INTRODUCTION
Thrombin, a serine proteinase that is intimately involved in blood coagulation, stimulates platelets at concentrations that are generated physiologically. The mechanism ofits action on platelets is not understood but appears to embody aspects both of an enzyme-catalysed reaction and of agonist-receptor equilibrium (Martin et al., 1975) . Though thrombin-induced release and aggregation require catalytically active thrombin (Martin et al., 1975) which removes a fragment from a membrane glycoprotein (GPV) (Berndt & Phillips, 198 la) , some effects strictly related to the binding of the enzyme to specific membrane receptors have been demonstrated. Phosphatidate synthesis as well as acid hydrolase secretion are tightly coupled to thrombin receptor occupancy in thrombin-stimulated platelets (Holmsen et al., 1984) . Moreover, when the platelet level of cyclic AMP is increased by prostaglandin E1, it may be decreased by ADP or adrenaline only if thrombin is bound to its receptors (Zavoico & Feinstein, 1984) .
Recently we observed that thrombin significantly increases cell adhesion to collagen interacting with platelets by a non-enzymic mechanism ; PMSF-inhibited thrombin was equally active in this respect and the phenomenon could be reversed by hirudin, an inhibitor of the macromolecular-binding site of thrombin (Tam et al., 1979) .
In order to gain more information about the mechanism by which thrombin influences platelet function, and since it is known that thrombin also modifies cytoskeleton organization, the Triton-insoluble residue was investigated after having treated platelets with PMSF-inhibited thrombin or after having removed active thrombin by hirudin. Moreover, since it is known that thrombin interacts with GPI and GPV (Okumura et al., 1978; Ganguly & Gould, 1979; Berndt & Phillips, 1981a,b) and that chymotrypsin is able to promote the breakdown of both these glycoproteins (Okumura & Jamieson, 1976; Detwiler, 1983) , platelets were treated with this enzyme and their ability to modify cytoskeleton assembly and collagen adhesiveness after thrombin treatment were investigated.
EXPERIMENTAL Materials
Human thrombin, calf-skin collagen, hirudin, achymotrypsin and human albumin (fraction V) were purchased from Sigma; Na125I and [14C]serotonin (5-hydroxytryptamine) were obtained from Amersham International; Sepharose 4B and Sephadex G-25 were from Pharmacia; tosyl-glycyl-prolyl-arginine-4-nitroanilide acetate (Chromozym TH) used for thrombin activity detection was from Boehringer Mannheim. All other reagents were analytical grade.
Platelet preparation
A suspension of washed human platelets was prepared as previously described (Balduini et al., 1984) Brass et al. (1976) with some modifications (Balduini et al., 1984) .
Abbreviations used: PMSF, phenylmethanesulphonyl fluoride; SDS, sodium dodecyl sulphate.
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Binding of thrombin to chymotrypsin-treated platelets Thrombin was labelled with 1251 by the Chloramine-T method as described by Tollefsen et al. (1974) and its binding to platelets was measured as previously described .
Serotonin release detection
When the release reaction had to be determined, washed platelets were preincubated with [14C]serotonin for 30 min at room temperature. Then platelets were pelletted by centrifugation in a Fischer Microfuge (12000 g) for 2 min in order to remove the excess of radioactivity and resuspended in the wash solution as previously described . The release caused by different treatments of platelets was adjusted by subtraction of the release due to platelet manipulation (i.e. centrifugation) only.
Inhibition of thrombin
Inhibition of thrombin at the active site with PMSF was performed as described by Lundblad (1971) . Proteolytic activity was tested using tosyl-glycyl-prolylarginine-4-nitroanilide acetate as substrate (Collen et al., 1980) ; clotting activity was determined as reported by Baughman (1970) . Both the tests proved the absence of any detectable residual activity even if a 10-fold higher concentration of the PMSF-thrombin was used. Platelets prepared as previously described were incubated with active thrombin or PMSF-thrombin at a final concentration of 6.6 nm. In order to remove active thrombin from the platelet surface, hirudin was added after 1 min to the thrombin-treated platelets in 1:5 molar ratio with the enzyme and the suspension was incubated for an additional 10 min at 37°C before cytoskeleton extraction.
Triton-insoluble residue analysis
Platelet cytoskeletons were prepared as described by Phillips et al. (1980) . At the desired time, Triton X-100 (10% ) in 50 mM-EGTA solution was added to the platelet suspension to a final concentration of 1 % Triton. The mixture was stirred for 1 min, cooled in ice for 30 min and the Triton X-100 residue was centrifuged in a Fischer Microfuge (12000 g) for4 min. The pellet was re-extracted with 0. 1% Triton, then dissolved in wash solution containing 20% SDS to give a final concentration of 2% SDS. The relative protein content of Triton-insoluble residue was evaluated by the method of Lowry et al. (1951) . Triton interference in the assay was suppressed according to Wang & Smith (1975) . Electrophoretic analysis of Triton-insoluble residue was performed according to Laemmli (1970) . Each sample contained an amount of protein that could be obtained from the same number of platelets (usually 5 x 107 cells), which ranged between 40 and 80 ,ug depending on the type of treatment that the platelets had undergone. Samples were dissolved by boiling for 10 min with 2% SDS, reduced with 4% 2-mercaptoethanol and then were electrophoresed by using 300 polyacrylamide for the stacking gel and a 5-15% -polyacrylamide exponential gradient for the separating gel. Electrophoresis was performed at constant voltage (25V/slab) until the Bromophenol Blue marker dye was within 1 cm of the bottom of the gel. Mr standards were routinely coelectrophoresed with samples. The gels were stained with Coomassie Blue for protein pattern visualization.
RESULTS
In our experimental conditions a partial activation of platelets probably occurs as a consequence of washing procedures; phase-contrast microscopy in fact usually showed some signs of shape modification also in untreated platelets. Thrombin treatment, in accordance with the data reported in the literature (Phillips et al., 1980; Rotman, 1984) , resulted in the typical cytoskeleton modifications consisting of an increase of protein content of the Triton-insoluble residue (Table 1 ) and in particular in the increase ofactin-binding protein, myosin, a-actinin and actin; moreover, additional bands with approximate Mr values of 68000, 55000 and 50000 appeared, corresponding to the a, ft and y chains of fibrinogen (Casella et al., 1983; Tuszinski et al., 1984) (Fig. 1 ) that in our experimental conditions probably coprecipitated with cytoskeletons. Triton-insoluble residue obtained from platelets incubated with active-site inhibited thrombin (PMSF-thrombin) showed an increased relative protein content similar to that obtained from platelets treated with the active enzyme (Table 1) ; the electrophoretic protein pattern did not show significant differences with respect to that obtained from the Triton-insoluble residue from thrombin-treated platelets, except that the three fibrinogen bands were obviously absent (Fig. 1) . The addition of hirudin, which in our experimental conditions removes most of bound 1251-thrombin (about 80%) , caused a decrease of protein content of the Triton-insoluble residue with respect to thrombin-activated platelets (Table 1) and an apparent concomitant decrease in the intensity of the bands of actin-binding protein, myosin, a-actinin and actin with respect to activated platelets; as expected, the three fibrinogen bands were still present since hirudin was added to the platelet suspension 1 min after thrombin addition. Chymotrypsin treatment of intact platelets, which is known to result in a decrease of GPI and GPV, did not cause a modification of the amount ofmembrane-bound 1251-thrombin, in accordance with the data of Tam et al. (1980) .
After incubation with 20 ,uM enzyme, a significant modification of cytoskeleton organization occurred, mainly consisting of the absence of actin-binding protein (Fig. 1) . After a further incubation with thrombin no modification of the protein content of Triton-insoluble residue was observed, and the cytoskeletal protein pattern was essentially unchanged (Fig. 1) . Chymotrypsintreated platelets showed a decrease in their adhesion to collagen; however, a further incubation with 6.6 nmthrombin was still able to increase the adhesiveness to the same extent as for intact platelets (Table 2) . Moreover, after 20,M-chymotrypsin treatment, platelets preincu- 
DISCUSSION
Despite a great number of investigations the mechanisms by which thrombin interacts with and stimulates platelets are not yet completely elucidated. It is known that this enzyme can act both by an enzymic and a receptor-mediated mechanism and that different interaction sites for thrombin are present on platelet membrane (Okumura et al., 1978; Ganguly & Gould, 1979; Berndt & Phillips, 1981a,b) .
Recently in our laboratory it was observed that thrombin increases platelet adhesion to collagen by a non-enzymic process . The evidence here reported is indicative that also the cytoskeletal modifications induced by thrombin are at least in part independent of its catalytic activity. PMSF-inhibited enzyme, in fact, is able, like active thrombin, though with a lower statistical significance level, to increase the protein content of the Triton-insoluble residue. Moreover the effect of the active enzyme on platelet cytoskeleton can be partially reversed by an additional incubation with hirudin, which is known to remove thrombin from the platelet surface. It seems therefore that the mechanism by which thrombin modifies cytoskeletal assembly depends on its interaction with the platelet surface, but not on its enzyme activity. It must be remarked that a similar mechanism was observed when the effect of thrombin, PMSF-thrombin and hirudin on platelet adhesion to collagen was investigated . It can therefore be speculated that the sequence ofevents by which thrombin triggers cytoskeletal modifications and increases platelet adhesiveness could in some way relate to each other. In an attempt to investigate this problem, platelets were treated with chymotrypsin, which is known to promote the breakdown of both GPlb and GPV, respectively a binding site and the substrate of thrombin on the platelet surface, and that, like other proteinases (Ascari et al., 1985) , reduces in our experimental conditions the adhesion of platelets to collagen by about 50%.
The cytoskeleton of20 ,sM-chymotrypsin-treated platelets is quantitatively unmodified with respect to untreated ones (Table 1) ; nevertheless, electrophoretic analysis Vol. 232 307 showed that the component with Mr 250000, corresponding to actin-binding protein, was totally lost. This protein, as well as P235, can be proteolysed by calcium-activated proteinases which are present in human platelets (Tsujinaka et al., 1982; Fox et al., 1985) , so that it can be hypothesized that its disappearance after chymotrypsin treatment could result from the increase of intracellular Ca2+ concentration with the consequent activation of these proteinases. However, chymotrypsintreated platelets, though still able to bind thrombin, are unresponsive to this ligand with respect to quantitative cytoskeletal modifications. On the other hand, though less reactive toward collagen, they increase their adhesiveness after thrombin treatment. It can therefore be concluded that the mechanisms by which thrombin stimulates platelets to adhere to collagen and to modify cytoskeletal assembly depend on the binding of the enzyme to the cell surface. However, the transducers of these interactions are probably different, since chymotrypsin digestion abolish thrombin's effects on the cytoskeleton but preserves its influence on adhesion to collagen. Though the targets of chymotrypsin action are known, it is impossible with our results to identify the molecular modulators of thrombin effects under investigation.
